ArticleBMC psychiatry2025
Abnormal serum IL-10 and IL-19 levels in childhood- and adolescent-onset schizophrenia: associations with negative symptoms and language function.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe pathophysiological mechanisms of childhood- and adolescent-onset schizophrenia (CAOS) remain incompletely understood, with cytokine abnormalities potentially playing an important role. This study aimed to investigate the relationships of altered serum interleukin (IL)-10 and IL-19 levels with the clinical symptoms and cognitive function of CAOS patients.
methodsThe cross-sectional study included 97 CAOS patients and 40 healthy controls. Serum IL-10 and IL-19 levels were measured. Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), and cognitive function was evaluated using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
resultsCompared to healthy controls, the CAOS patients had significantly lower serum IL-10 levels (p = 0.005) and higher IL-19 levels (p = 0.046). IL-10 was significantly negatively correlated with PANSS negative symptoms (r=-0.338, p = 0.001). The CAOS patients performed significantly worse than healthy controls across all RBANS cognitive domains (all p < 0.001), with significant correlations observed between the severity of clinical symptoms and cognitive impairment. In the healthy controls, IL-10 was significantly negatively correlated with language (r=-0.394, p = 0.012), whereas no such correlation was observed in the CAOS patients (p > 0.05). Low IL-10 levels were significantly associated with CAOS (B = 0.387, p = 0.002, RR = 1.472, 95% CI: 1.159–1.870), with a population attributable fraction of 19.1%. The association between IL-19 and CAOS did not reach statistical significance (B = 0.217, p = 0.081, RR = 1.243, 95% CI: 0.973–1.586).
conclusionsThe CAOS patients had decreased IL-10 and increased IL-19 serum levels, with IL-10 levels associated with negative symptoms and language. These results suggest that IL-10 may serve as a potential biological marker associated with CAOS susceptibility, while the role of IL-19 requires further investigation. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.